A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways

HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2016-12, Vol.11 (12), p.e0167397-e0167397
Hauptverfasser: Hamy, Anne-Sophie, Bonsang-Kitzis, Hélène, Lae, Marick, Moarii, Matahi, Sadacca, Benjamin, Pinheiro, Alice, Galliot, Marion, Abecassis, Judith, Laurent, Cecile, Reyal, Fabien
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e0167397
container_issue 12
container_start_page e0167397
container_title PloS one
container_volume 11
creator Hamy, Anne-Sophie
Bonsang-Kitzis, Hélène
Lae, Marick
Moarii, Matahi
Sadacca, Benjamin
Pinheiro, Alice
Galliot, Marion
Abecassis, Judith
Laurent, Cecile
Reyal, Fabien
description HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions. We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC. We then used external public datasets to assess the ability of these metagenes to predict the response to chemotherapy (Ignatiadis dataset), and prognosis (METABRIC dataset). We identified a six-metagene signature (138 genes) containing metagenes enriched in different gene ontologies. The gene clusters were named as follows: Immunity, Tumor suppressors/proliferation, Interferon, Signal transduction, Hormone/survival and Matrix clusters. In all datasets, the Immunity metagene was less strongly expressed in ER-positive than in ER-negative tumors, and was inversely correlated with the Hormonal/survival metagene. Within the signature, multivariate analyses showed that strong expression of the "Immunity" metagene was associated with higher pCR rates after NAC (OR = 3.71[1.28-11.91], p = 0.019) than weak expression, and with a better prognosis in HER2-positive/ER-negative breast cancers (HR = 0.58 [0.36-0.94], p = 0.026). Immunity metagene expression was associated with the presence of tumor-infiltrating lymphocytes (TILs). The identification of a predictive and prognostic immune module in HER2-positive BC confirms the need for clinical testing for immune checkpoint modulators and vaccines for this specific subtype. The inverse correlation between Immunity and hormone pathways opens research perspectives and deserves further investigation.
doi_str_mv 10.1371/journal.pone.0167397
format Article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1851683490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A474759866</galeid><doaj_id>oai_doaj_org_article_db196c48dbfa4fbc918d578b4d9e1954</doaj_id><sourcerecordid>A474759866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c725t-fbbbe9a2219c3a662697f970e98c0512d0a0db27e30059a070c8b3650a89732a3</originalsourceid><addsrcrecordid>eNqNk11v0zAUhiMEYmPwDxBYmoRAosXOp32DVKrBKg02bcCtdZKcNKkcu9hOR_8hPwt366YVdjH5wlbyvK-Pz0cUvWR0zJKCfViYwWpQ46XROKYsLxJRPIr2mUjiUR7T5PGd8170zLkFpVnC8_xptBfzcBY034_-TMiFt6YHRWZ9P2gkX009KCRTYy0q8FiTy863xLdIztGF2xwSb8g3NFAvhhVoT6Yt9iYAFpbr9-TMmrk2rnMEdE1O1v2yNdXaI5npplPegu-MJp0mx0fn8egskL5bIflkEVzwAlt1OgREZi4oVmgdqvV_4Rwb25vwfHIGvr2EtXsePWlAOXyx3Q-iH5-Pvk-PRyenX2bTycmoKuLMj5qyLFFAHDNRJZDncS6KRhQUBa9oxuKaAq3LuMBkkyGgBa14meQZBS6KJIbkIHp97btUxsltEZxkPGM5T1JBAzG7JmoDC7m0XQ92LQ108uqDsXMJ1neVQlmXTORVyuuygbQpK8F4nRW8TGuBTGRp8Pq4vW0oe6wr1CF_asd094_uWjk3K5mxggvBg8HbrYE1vwZ0Xvadq1Ap0GiGq7hFynkSpw9B44Kz-Ao9_Ae9PxFbag7hrZ1uTAix2pjKSVqkRSZCNwZqfA8VVo19V4XmDk2Du4J3O4LAePzt5zA4J2cX5w9nT3_usm_usC2C8q0zati0q9sF02uwssY5i81tPRiVm9m8yYbczKbczmaQvbpby1vRzTAmfwF-mjd7</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1851683490</pqid></control><display><type>article</type><title>A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Hamy, Anne-Sophie ; Bonsang-Kitzis, Hélène ; Lae, Marick ; Moarii, Matahi ; Sadacca, Benjamin ; Pinheiro, Alice ; Galliot, Marion ; Abecassis, Judith ; Laurent, Cecile ; Reyal, Fabien</creator><contributor>Coleman, William B.</contributor><creatorcontrib>Hamy, Anne-Sophie ; Bonsang-Kitzis, Hélène ; Lae, Marick ; Moarii, Matahi ; Sadacca, Benjamin ; Pinheiro, Alice ; Galliot, Marion ; Abecassis, Judith ; Laurent, Cecile ; Reyal, Fabien ; Coleman, William B.</creatorcontrib><description>HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions. We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC. We then used external public datasets to assess the ability of these metagenes to predict the response to chemotherapy (Ignatiadis dataset), and prognosis (METABRIC dataset). We identified a six-metagene signature (138 genes) containing metagenes enriched in different gene ontologies. The gene clusters were named as follows: Immunity, Tumor suppressors/proliferation, Interferon, Signal transduction, Hormone/survival and Matrix clusters. In all datasets, the Immunity metagene was less strongly expressed in ER-positive than in ER-negative tumors, and was inversely correlated with the Hormonal/survival metagene. Within the signature, multivariate analyses showed that strong expression of the "Immunity" metagene was associated with higher pCR rates after NAC (OR = 3.71[1.28-11.91], p = 0.019) than weak expression, and with a better prognosis in HER2-positive/ER-negative breast cancers (HR = 0.58 [0.36-0.94], p = 0.026). Immunity metagene expression was associated with the presence of tumor-infiltrating lymphocytes (TILs). The identification of a predictive and prognostic immune module in HER2-positive BC confirms the need for clinical testing for immune checkpoint modulators and vaccines for this specific subtype. The inverse correlation between Immunity and hormone pathways opens research perspectives and deserves further investigation.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0167397</identifier><identifier>PMID: 28005906</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adjuvant chemotherapy ; Adult ; Analysis ; Arrays ; Biological response modifiers ; Biology ; Biology and Life Sciences ; Breast cancer ; Breast carcinoma ; Breast Neoplasms - immunology ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer ; Cancer therapies ; Carcinoma - immunology ; Carcinoma - mortality ; Carcinoma - pathology ; Carcinoma - therapy ; Care and treatment ; Cell Line, Tumor ; Chemotherapy ; Clusters ; Databases, Factual ; Datasets ; Development and progression ; ErbB-2 protein ; Female ; Gene clusters ; Gene expression ; Health aspects ; Humans ; Immune checkpoint ; Immunity ; Infiltration ; Interferon ; Kinases ; Laboratories ; Lymphocytes ; Lymphocytes, Tumor-Infiltrating - immunology ; Medical prognosis ; Medicine and Health Sciences ; Metastases ; Metastasis ; Middle Aged ; Models, Biological ; Modulators ; Multigene Family ; Neoadjuvant Therapy ; Physical Sciences ; Predictions ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Research and Analysis Methods ; Suppressors ; Survival ; Therapeutic applications ; Transcriptome ; Transduction ; Tumor-infiltrating lymphocytes ; Tumors ; Vaccines</subject><ispartof>PloS one, 2016-12, Vol.11 (12), p.e0167397-e0167397</ispartof><rights>COPYRIGHT 2016 Public Library of Science</rights><rights>2016 Hamy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 Hamy et al 2016 Hamy et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c725t-fbbbe9a2219c3a662697f970e98c0512d0a0db27e30059a070c8b3650a89732a3</citedby><cites>FETCH-LOGICAL-c725t-fbbbe9a2219c3a662697f970e98c0512d0a0db27e30059a070c8b3650a89732a3</cites><orcidid>0000-0003-4430-3022</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178998/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178998/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23847,27903,27904,53769,53771,79346,79347</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28005906$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Coleman, William B.</contributor><creatorcontrib>Hamy, Anne-Sophie</creatorcontrib><creatorcontrib>Bonsang-Kitzis, Hélène</creatorcontrib><creatorcontrib>Lae, Marick</creatorcontrib><creatorcontrib>Moarii, Matahi</creatorcontrib><creatorcontrib>Sadacca, Benjamin</creatorcontrib><creatorcontrib>Pinheiro, Alice</creatorcontrib><creatorcontrib>Galliot, Marion</creatorcontrib><creatorcontrib>Abecassis, Judith</creatorcontrib><creatorcontrib>Laurent, Cecile</creatorcontrib><creatorcontrib>Reyal, Fabien</creatorcontrib><title>A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions. We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC. We then used external public datasets to assess the ability of these metagenes to predict the response to chemotherapy (Ignatiadis dataset), and prognosis (METABRIC dataset). We identified a six-metagene signature (138 genes) containing metagenes enriched in different gene ontologies. The gene clusters were named as follows: Immunity, Tumor suppressors/proliferation, Interferon, Signal transduction, Hormone/survival and Matrix clusters. In all datasets, the Immunity metagene was less strongly expressed in ER-positive than in ER-negative tumors, and was inversely correlated with the Hormonal/survival metagene. Within the signature, multivariate analyses showed that strong expression of the "Immunity" metagene was associated with higher pCR rates after NAC (OR = 3.71[1.28-11.91], p = 0.019) than weak expression, and with a better prognosis in HER2-positive/ER-negative breast cancers (HR = 0.58 [0.36-0.94], p = 0.026). Immunity metagene expression was associated with the presence of tumor-infiltrating lymphocytes (TILs). The identification of a predictive and prognostic immune module in HER2-positive BC confirms the need for clinical testing for immune checkpoint modulators and vaccines for this specific subtype. The inverse correlation between Immunity and hormone pathways opens research perspectives and deserves further investigation.</description><subject>Adjuvant chemotherapy</subject><subject>Adult</subject><subject>Analysis</subject><subject>Arrays</subject><subject>Biological response modifiers</subject><subject>Biology</subject><subject>Biology and Life Sciences</subject><subject>Breast cancer</subject><subject>Breast carcinoma</subject><subject>Breast Neoplasms - immunology</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma - immunology</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - therapy</subject><subject>Care and treatment</subject><subject>Cell Line, Tumor</subject><subject>Chemotherapy</subject><subject>Clusters</subject><subject>Databases, Factual</subject><subject>Datasets</subject><subject>Development and progression</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Gene clusters</subject><subject>Gene expression</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immunity</subject><subject>Infiltration</subject><subject>Interferon</subject><subject>Kinases</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Medical prognosis</subject><subject>Medicine and Health Sciences</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Models, Biological</subject><subject>Modulators</subject><subject>Multigene Family</subject><subject>Neoadjuvant Therapy</subject><subject>Physical Sciences</subject><subject>Predictions</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Research and Analysis Methods</subject><subject>Suppressors</subject><subject>Survival</subject><subject>Therapeutic applications</subject><subject>Transcriptome</subject><subject>Transduction</subject><subject>Tumor-infiltrating lymphocytes</subject><subject>Tumors</subject><subject>Vaccines</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11v0zAUhiMEYmPwDxBYmoRAosXOp32DVKrBKg02bcCtdZKcNKkcu9hOR_8hPwt366YVdjH5wlbyvK-Pz0cUvWR0zJKCfViYwWpQ46XROKYsLxJRPIr2mUjiUR7T5PGd8170zLkFpVnC8_xptBfzcBY034_-TMiFt6YHRWZ9P2gkX009KCRTYy0q8FiTy863xLdIztGF2xwSb8g3NFAvhhVoT6Yt9iYAFpbr9-TMmrk2rnMEdE1O1v2yNdXaI5npplPegu-MJp0mx0fn8egskL5bIflkEVzwAlt1OgREZi4oVmgdqvV_4Rwb25vwfHIGvr2EtXsePWlAOXyx3Q-iH5-Pvk-PRyenX2bTycmoKuLMj5qyLFFAHDNRJZDncS6KRhQUBa9oxuKaAq3LuMBkkyGgBa14meQZBS6KJIbkIHp97btUxsltEZxkPGM5T1JBAzG7JmoDC7m0XQ92LQ108uqDsXMJ1neVQlmXTORVyuuygbQpK8F4nRW8TGuBTGRp8Pq4vW0oe6wr1CF_asd094_uWjk3K5mxggvBg8HbrYE1vwZ0Xvadq1Ap0GiGq7hFynkSpw9B44Kz-Ao9_Ae9PxFbag7hrZ1uTAix2pjKSVqkRSZCNwZqfA8VVo19V4XmDk2Du4J3O4LAePzt5zA4J2cX5w9nT3_usm_usC2C8q0zati0q9sF02uwssY5i81tPRiVm9m8yYbczKbczmaQvbpby1vRzTAmfwF-mjd7</recordid><startdate>20161222</startdate><enddate>20161222</enddate><creator>Hamy, Anne-Sophie</creator><creator>Bonsang-Kitzis, Hélène</creator><creator>Lae, Marick</creator><creator>Moarii, Matahi</creator><creator>Sadacca, Benjamin</creator><creator>Pinheiro, Alice</creator><creator>Galliot, Marion</creator><creator>Abecassis, Judith</creator><creator>Laurent, Cecile</creator><creator>Reyal, Fabien</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4430-3022</orcidid></search><sort><creationdate>20161222</creationdate><title>A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways</title><author>Hamy, Anne-Sophie ; Bonsang-Kitzis, Hélène ; Lae, Marick ; Moarii, Matahi ; Sadacca, Benjamin ; Pinheiro, Alice ; Galliot, Marion ; Abecassis, Judith ; Laurent, Cecile ; Reyal, Fabien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c725t-fbbbe9a2219c3a662697f970e98c0512d0a0db27e30059a070c8b3650a89732a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adjuvant chemotherapy</topic><topic>Adult</topic><topic>Analysis</topic><topic>Arrays</topic><topic>Biological response modifiers</topic><topic>Biology</topic><topic>Biology and Life Sciences</topic><topic>Breast cancer</topic><topic>Breast carcinoma</topic><topic>Breast Neoplasms - immunology</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma - immunology</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - therapy</topic><topic>Care and treatment</topic><topic>Cell Line, Tumor</topic><topic>Chemotherapy</topic><topic>Clusters</topic><topic>Databases, Factual</topic><topic>Datasets</topic><topic>Development and progression</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Gene clusters</topic><topic>Gene expression</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immunity</topic><topic>Infiltration</topic><topic>Interferon</topic><topic>Kinases</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Medical prognosis</topic><topic>Medicine and Health Sciences</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Models, Biological</topic><topic>Modulators</topic><topic>Multigene Family</topic><topic>Neoadjuvant Therapy</topic><topic>Physical Sciences</topic><topic>Predictions</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Research and Analysis Methods</topic><topic>Suppressors</topic><topic>Survival</topic><topic>Therapeutic applications</topic><topic>Transcriptome</topic><topic>Transduction</topic><topic>Tumor-infiltrating lymphocytes</topic><topic>Tumors</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamy, Anne-Sophie</creatorcontrib><creatorcontrib>Bonsang-Kitzis, Hélène</creatorcontrib><creatorcontrib>Lae, Marick</creatorcontrib><creatorcontrib>Moarii, Matahi</creatorcontrib><creatorcontrib>Sadacca, Benjamin</creatorcontrib><creatorcontrib>Pinheiro, Alice</creatorcontrib><creatorcontrib>Galliot, Marion</creatorcontrib><creatorcontrib>Abecassis, Judith</creatorcontrib><creatorcontrib>Laurent, Cecile</creatorcontrib><creatorcontrib>Reyal, Fabien</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamy, Anne-Sophie</au><au>Bonsang-Kitzis, Hélène</au><au>Lae, Marick</au><au>Moarii, Matahi</au><au>Sadacca, Benjamin</au><au>Pinheiro, Alice</au><au>Galliot, Marion</au><au>Abecassis, Judith</au><au>Laurent, Cecile</au><au>Reyal, Fabien</au><au>Coleman, William B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2016-12-22</date><risdate>2016</risdate><volume>11</volume><issue>12</issue><spage>e0167397</spage><epage>e0167397</epage><pages>e0167397-e0167397</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions. We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC. We then used external public datasets to assess the ability of these metagenes to predict the response to chemotherapy (Ignatiadis dataset), and prognosis (METABRIC dataset). We identified a six-metagene signature (138 genes) containing metagenes enriched in different gene ontologies. The gene clusters were named as follows: Immunity, Tumor suppressors/proliferation, Interferon, Signal transduction, Hormone/survival and Matrix clusters. In all datasets, the Immunity metagene was less strongly expressed in ER-positive than in ER-negative tumors, and was inversely correlated with the Hormonal/survival metagene. Within the signature, multivariate analyses showed that strong expression of the "Immunity" metagene was associated with higher pCR rates after NAC (OR = 3.71[1.28-11.91], p = 0.019) than weak expression, and with a better prognosis in HER2-positive/ER-negative breast cancers (HR = 0.58 [0.36-0.94], p = 0.026). Immunity metagene expression was associated with the presence of tumor-infiltrating lymphocytes (TILs). The identification of a predictive and prognostic immune module in HER2-positive BC confirms the need for clinical testing for immune checkpoint modulators and vaccines for this specific subtype. The inverse correlation between Immunity and hormone pathways opens research perspectives and deserves further investigation.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>28005906</pmid><doi>10.1371/journal.pone.0167397</doi><tpages>e0167397</tpages><orcidid>https://orcid.org/0000-0003-4430-3022</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2016-12, Vol.11 (12), p.e0167397-e0167397
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1851683490
source Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry
subjects Adjuvant chemotherapy
Adult
Analysis
Arrays
Biological response modifiers
Biology
Biology and Life Sciences
Breast cancer
Breast carcinoma
Breast Neoplasms - immunology
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer
Cancer therapies
Carcinoma - immunology
Carcinoma - mortality
Carcinoma - pathology
Carcinoma - therapy
Care and treatment
Cell Line, Tumor
Chemotherapy
Clusters
Databases, Factual
Datasets
Development and progression
ErbB-2 protein
Female
Gene clusters
Gene expression
Health aspects
Humans
Immune checkpoint
Immunity
Infiltration
Interferon
Kinases
Laboratories
Lymphocytes
Lymphocytes, Tumor-Infiltrating - immunology
Medical prognosis
Medicine and Health Sciences
Metastases
Metastasis
Middle Aged
Models, Biological
Modulators
Multigene Family
Neoadjuvant Therapy
Physical Sciences
Predictions
Prognosis
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Research and Analysis Methods
Suppressors
Survival
Therapeutic applications
Transcriptome
Transduction
Tumor-infiltrating lymphocytes
Tumors
Vaccines
title A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A50%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Stromal%20Immune%20Module%20Correlated%20with%20the%20Response%20to%20Neoadjuvant%20Chemotherapy,%20Prognosis%20and%20Lymphocyte%20Infiltration%20in%20HER2-Positive%20Breast%20Carcinoma%20Is%20Inversely%20Correlated%20with%20Hormonal%20Pathways&rft.jtitle=PloS%20one&rft.au=Hamy,%20Anne-Sophie&rft.date=2016-12-22&rft.volume=11&rft.issue=12&rft.spage=e0167397&rft.epage=e0167397&rft.pages=e0167397-e0167397&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0167397&rft_dat=%3Cgale_plos_%3EA474759866%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1851683490&rft_id=info:pmid/28005906&rft_galeid=A474759866&rft_doaj_id=oai_doaj_org_article_db196c48dbfa4fbc918d578b4d9e1954&rfr_iscdi=true